Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 25, 2026, titled "Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy".
Press Release Feb 25 2026
Filed with NSE · · 3 pages · English
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 19 2026
- Press Release Feb 18 2026
- Press Release Feb 17 2026
- Press Release Feb 14 2026
- Press Release 10-02-2026 NewspaperPublication10022026
Later from Zydus Lifesciences
- Press Release Feb 27 2026
- Press Release Feb 28 2026
- Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
- Press Release Mar 12 2026
- Press Release Mar 13 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences